ReviewCurrent oncology (Toronto, Ont.)2025

Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review.

Sotiris Loizidis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.